0 XP   0   0   0

Vivoryon Therapeutics NV
Buy, Hold or Sell?

Let's analyse Vivoryon together

PenkeI guess you are interested in Vivoryon Therapeutics NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vivoryon Therapeutics NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vivoryon Therapeutics NV

I send you an email if I find something interesting about Vivoryon Therapeutics NV.

Quick analysis of Vivoryon (30 sec.)










1. Valuation of Vivoryon (5 min.)




Current price per share

€14.18

2. Growth of Vivoryon (5 min.)




Is Vivoryon growing?

Current yearPrevious yearGrowGrow %
How rich?$17.7m$28m-$10.3m-58.4%

How much money is Vivoryon making?

Current yearPrevious yearGrowGrow %
Making money-$13.5m-$17.6m$4.1m?
Net Profit Margin-117.6%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Vivoryon (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#749 / 1215

Most Revenue
#290 / 1215

Most Profit
#742 / 1215

Most Efficient
#724 / 1215


Fundamentals of Vivoryon

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Vivoryon Therapeutics NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vivoryon earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • A Net Profit Margin of -117.6% means that €-1.18 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is -117.6%. The company is making a huge loss. -2
  • The TTM is -117.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-117.6%TTM-117.6%0.0%
TTM-117.6%YOY--117.6%
TTM-117.6%5Y-23.5%-94.1%
5Y-23.5%10Y-19.6%-3.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-117.6%-193.4%+75.8%
TTM-117.6%-273.6%+156.0%
YOY--315.2%+315.2%
5Y-23.5%-539.0%+515.5%
10Y-19.6%-664.9%+645.3%
1.1.2. Return on Assets

Shows how efficient Vivoryon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • -51.6% Return on Assets means that Vivoryon generated €-0.52 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vivoryon Therapeutics NV:

  • The MRQ is -51.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -51.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-51.6%TTM-51.6%0.0%
TTM-51.6%YOY-55.5%+3.9%
TTM-51.6%5Y-77.9%+26.3%
5Y-77.9%10Y-75.3%-2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-51.6%-12.3%-39.3%
TTM-51.6%-12.4%-39.2%
YOY-55.5%-10.9%-44.6%
5Y-77.9%-15.3%-62.6%
10Y-75.3%-17.6%-57.7%
1.1.3. Return on Equity

Shows how efficient Vivoryon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • -76.4% Return on Equity means Vivoryon generated €-0.76 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vivoryon Therapeutics NV:

  • The MRQ is -76.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -76.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-76.4%TTM-76.4%0.0%
TTM-76.4%YOY-63.0%-13.5%
TTM-76.4%5Y-175.3%+98.9%
5Y-175.3%10Y-160.2%-15.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-76.4%-15.2%-61.2%
TTM-76.4%-15.5%-60.9%
YOY-63.0%-13.1%-49.9%
5Y-175.3%-20.4%-154.9%
10Y-160.2%-20.9%-139.3%

1.2. Operating Efficiency of Vivoryon Therapeutics NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vivoryon is operating .

  • Measures how much profit Vivoryon makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • An Operating Margin of -118.9% means the company generated €-1.19  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is -118.9%. The company is operating very inefficient. -2
  • The TTM is -118.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-118.9%TTM-118.9%0.0%
TTM-118.9%YOY--118.9%
TTM-118.9%5Y-23.8%-95.1%
5Y-23.8%10Y-19.8%-4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-118.9%-316.7%+197.8%
TTM-118.9%-267.4%+148.5%
YOY--333.8%+333.8%
5Y-23.8%-517.0%+493.2%
10Y-19.8%-624.7%+604.9%
1.2.2. Operating Ratio

Measures how efficient Vivoryon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.34 means that the operating costs are €2.34 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 2.344. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.344. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.344TTM2.3440.000
TTM2.344YOY-+2.344
TTM2.3445Y0.469+1.875
5Y0.46910Y0.391+0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3442.989-0.645
TTM2.3443.644-1.300
YOY-4.537-4.537
5Y0.4696.411-5.942
10Y0.3918.312-7.921

1.3. Liquidity of Vivoryon Therapeutics NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vivoryon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.00 means the company has €4.00 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 4.005. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.005. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.005TTM4.0050.000
TTM4.005YOY21.731-17.726
TTM4.0055Y18.933-14.928
5Y18.93310Y16.498+2.436
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0054.559-0.554
TTM4.0054.993-0.988
YOY21.7316.149+15.582
5Y18.9336.306+12.627
10Y16.4986.588+9.910
1.3.2. Quick Ratio

Measures if Vivoryon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • A Quick Ratio of 0.67 means the company can pay off €0.67 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.667. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.667. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.667TTM0.6670.000
TTM0.667YOY0.097+0.569
TTM0.6675Y0.301+0.365
5Y0.30110Y0.256+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6673.874-3.207
TTM0.6674.499-3.832
YOY0.0975.772-5.675
5Y0.3015.816-5.515
10Y0.2566.032-5.776

1.4. Solvency of Vivoryon Therapeutics NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vivoryon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vivoryon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.32 means that Vivoryon assets are financed with 32.5% credit (debt) and the remaining percentage (100% - 32.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.325. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.325. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.325TTM0.3250.000
TTM0.325YOY0.119+0.206
TTM0.3255Y0.276+0.049
5Y0.27610Y0.275+0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3250.311+0.014
TTM0.3250.298+0.027
YOY0.1190.269-0.150
5Y0.2760.377-0.101
10Y0.2750.409-0.134
1.4.2. Debt to Equity Ratio

Measures if Vivoryon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 48.1% means that company has €0.48 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.481. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.481. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.481TTM0.4810.000
TTM0.481YOY0.135+0.346
TTM0.4815Y0.638-0.157
5Y0.63810Y0.592+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4810.363+0.118
TTM0.4810.362+0.119
YOY0.1350.277-0.142
5Y0.6380.425+0.213
10Y0.5920.463+0.129

2. Market Valuation of Vivoryon Therapeutics NV

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Vivoryon generates.

  • Above 15 is considered overpriced but always compare Vivoryon to the Biotechnology industry mean.
  • A PE ratio of -36.19 means the investor is paying €-36.19 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is -27.010. Company is losing money. -2
  • The MRQ is -36.191. Company is losing money. -2
  • The TTM is -36.191. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-27.010MRQ-36.191+9.181
MRQ-36.191TTM-36.1910.000
TTM-36.191YOY-13.155-23.036
TTM-36.1915Y-21.198-14.994
5Y-21.19810Y-22.878+1.680
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-27.010-6.478-20.532
MRQ-36.191-7.165-29.026
TTM-36.191-8.420-27.771
YOY-13.155-19.867+6.712
5Y-21.198-18.328-2.870
10Y-22.878-18.055-4.823
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Vivoryon.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is -29.340. Very Bad. -2
  • The TTM is -29.340. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-29.340TTM-29.3400.000
TTM-29.340YOY119.110-148.451
TTM-29.3405Y8.538-37.879
5Y8.53810Y8.5380.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.340-4.292-25.048
TTM-29.340-6.108-23.232
YOY119.110-13.925+133.035
5Y8.538-12.525+21.063
10Y8.538-11.713+20.251

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vivoryon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 27.66 means the investor is paying €27.66 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is 20.645. Seems overpriced? -1
  • The MRQ is 27.662. Seems overpriced? -1
  • The TTM is 27.662. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD20.645MRQ27.662-7.017
MRQ27.662TTM27.6620.000
TTM27.662YOY8.283+19.379
TTM27.6625Y23.565+4.097
5Y23.56510Y24.060-0.495
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.6451.890+18.755
MRQ27.6622.024+25.638
TTM27.6622.335+25.327
YOY8.2833.965+4.318
5Y23.5653.738+19.827
10Y24.0604.002+20.058
2. Total Gains per Share

2.4. Latest News of Vivoryon Therapeutics NV

Does Vivoryon Therapeutics NV still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Vivoryon Therapeutics NV to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2023-06-01
07:00
Vivoryon Therapeutics N.V. to Participate in Upcoming ConferencesRead
2023-05-26
07:39
Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 MillionRead
2023-05-25
17:50
Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild OfferingRead
2023-05-16
07:00
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational ProgressRead
2023-05-09
07:02
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023Read
2023-05-09
07:00
Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023Read

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Vivoryon Therapeutics NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.401-0.4010%-0.682+70%0.002-26796%0.114-450%
Book Value Growth--0.6310.6310%0.615+3%7.323-91%7.323-91%
Book Value Per Share--0.6870.6870%1.088-37%0.793-13%0.774-11%
Book Value Per Share Growth--0.6310.6310%0.615+3%7.323-91%7.323-91%
Current Ratio--4.0054.0050%21.731-82%18.933-79%16.498-76%
Debt To Asset Ratio--0.3250.3250%0.119+174%0.276+18%0.275+18%
Debt To Equity Ratio--0.4810.4810%0.135+257%0.638-25%0.592-19%
Dividend Per Share----0%-0%-0%-0%
Eps---0.525-0.5250%-0.685+30%-0.438-17%-0.461-12%
Eps Growth--1.2331.2330%-0.110+109%0.914+35%0.914+35%
Free Cash Flow Per Share---0.468-0.4680%-0.608+30%-0.471+1%-0.484+3%
Free Cash Flow Per Share Growth--1.2301.2300%0.743+66%0.964+28%0.964+28%
Free Cash Flow To Equity Per Share---0.502-0.5020%-0.612+22%0.342-247%0.289-274%
Free Cash Flow To Equity Per Share Growth--1.1781.1780%-0.391+133%-2.233+290%-2.233+290%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.003--------
Intrinsic Value_10Y_min---0.998--------
Intrinsic Value_1Y_max---0.430--------
Intrinsic Value_1Y_min---0.418--------
Intrinsic Value_3Y_max---1.042--------
Intrinsic Value_3Y_min---0.988--------
Intrinsic Value_5Y_max---1.350--------
Intrinsic Value_5Y_min---1.260--------
Net Profit Margin---1.176-1.1760%--100%-0.235-80%-0.196-83%
Operating Margin---1.189-1.1890%--100%-0.238-80%-0.198-83%
Operating Ratio--2.3442.3440%-+100%0.469+400%0.391+500%
Pb Ratio20.645-34%27.66227.6620%8.283+234%23.565+17%24.060+15%
Pe Ratio-27.010+25%-36.191-36.1910%-13.155-64%-21.198-41%-22.878-37%
Peg Ratio---29.340-29.3400%119.110-125%8.538-444%8.538-444%
Price Per Share14.180-34%19.00019.0000%9.010+111%9.322+104%10.773+76%
Price To Total Gains Ratio-35.370+25%-47.392-47.3920%-13.208-72%-19.948-58%-12.201-74%
Profit Growth--1.2331.2330%-0.110+109%0.914+35%0.914+35%
Quick Ratio--0.6670.6670%0.097+585%0.301+121%0.256+160%
Return On Assets---0.516-0.5160%-0.555+8%-0.779+51%-0.753+46%
Return On Equity---0.764-0.7640%-0.630-18%-1.753+129%-1.602+110%
Total Gains Per Share---0.401-0.4010%-0.682+70%0.002-26796%0.114-450%
Total Gains Per Share Growth--1.4121.4120%-0.397+128%1.783-21%1.783-21%
Usd Book Value--17740825.50017740825.5000%28095801.500-37%20486222.800-13%19996333.000-11%
Usd Book Value Change Per Share---0.430-0.4300%-0.731+70%0.002-26796%0.123-450%
Usd Book Value Per Share--0.7360.7360%1.166-37%0.850-13%0.830-11%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.563-0.5630%-0.734+30%-0.469-17%-0.494-12%
Usd Free Cash Flow---12091877.500-12091877.5000%-15699618.000+30%-12156596.100+1%-12498868.917+3%
Usd Free Cash Flow Per Share---0.502-0.5020%-0.651+30%-0.504+1%-0.519+3%
Usd Free Cash Flow To Equity Per Share---0.538-0.5380%-0.655+22%0.366-247%0.310-274%
Usd Price Per Share15.194-34%20.35920.3590%9.654+111%9.989+104%11.543+76%
Usd Profit---13559832.500-13559832.5000%-17690465.000+30%-11300896.200-17%-11898114.583-12%
Usd Revenue--11533626.00011533626.0000%-+100%2306725.200+400%1922271.000+500%
Usd Total Gains Per Share---0.430-0.4300%-0.731+70%0.002-26796%0.123-450%
 EOD+3 -2MRQTTM+0 -0YOY+25 -135Y+15 -2310Y+15 -23

3.2. Fundamental Score

Let's check the fundamental score of Vivoryon Therapeutics NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-27.010
Price to Book Ratio (EOD)Between0-120.645
Net Profit Margin (MRQ)Greater than0-1.176
Operating Margin (MRQ)Greater than0-1.189
Quick Ratio (MRQ)Greater than10.667
Current Ratio (MRQ)Greater than14.005
Debt to Asset Ratio (MRQ)Less than10.325
Debt to Equity Ratio (MRQ)Less than10.481
Return on Equity (MRQ)Greater than0.15-0.764
Return on Assets (MRQ)Greater than0.05-0.516
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Vivoryon Therapeutics NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose14.320
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets24,520
Total Liabilities7,963
Total Stockholder Equity16,557
 As reported
Total Liabilities 7,963
Total Stockholder Equity+ 16,557
Total Assets = 24,520

Assets

Total Assets24,520
Total Current Assets20,229
Long-term Assets20,229
Total Current Assets
Cash And Cash Equivalents 14,661
Short-term Investments 7
Net Receivables 3,360
Other Current Assets 1,888
Total Current Assets  (as reported)20,229
Total Current Assets  (calculated)19,916
+/- 313
Long-term Assets
Property Plant Equipment 285
Intangible Assets 533
Other Assets 3,473
Long-term Assets  (as reported)4,291
Long-term Assets  (calculated)4,291
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,051
Long-term Liabilities2,912
Total Stockholder Equity16,557
Total Current Liabilities
Accounts payable 4,360
Other Current Liabilities 366
Total Current Liabilities  (as reported)5,051
Total Current Liabilities  (calculated)4,726
+/- 325
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt224
Other Liabilities 2,780
Long-term Liabilities  (as reported)2,912
Long-term Liabilities  (calculated)3,004
+/- 92
Total Stockholder Equity
Common Stock20,050
Other Stockholders Equity 6,168
Total Stockholder Equity (as reported)16,557
Total Stockholder Equity (calculated)26,218
+/- 9,661
Other
Capital Stock20,050
Common Stock Shares Outstanding 22,050
Net Invested Capital 16,557
Net Tangible Assets 16,024
Net Working Capital 15,178



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
22,366
10,762
4,048
45,861
29,751
24,520
24,52029,75145,8614,04810,76222,366
   > Total Current Assets 
22,199
10,693
3,982
45,377
28,793
20,229
20,22928,79345,3773,98210,69322,199
       Cash And Cash Equivalents 
21,897
10,291
3,783
41,524
26,306
14,661
14,66126,30641,5243,78310,29121,897
       Short-term Investments 
0
0
0
0
0
7
700000
       Net Receivables 
166
0
91
602
129
3,360
3,360129602910166
       Other Current Assets 
10
402
7
21
21
1,888
1,8882121740210
   > Long-term Assets 
167
69
66
484
958
4,291
4,2919584846669167
       Property Plant Equipment 
68
55
56
465
390
285
285390465565568
       Intangible Assets 
96
12
7
16
565
533
5335651671296
       Other Assets 
0
0
3
3
3
3,473
3,47333300
> Total Liabilities 
5,990
1,839
2,818
3,196
3,530
7,963
7,9633,5303,1962,8181,8395,990
   > Total Current Liabilities 
5,140
668
964
930
1,325
5,051
5,0511,3259309646685,140
       Accounts payable 
1,893
344
772
539
911
4,360
4,3609115397723441,893
       Other Current Liabilities 
2,897
75
110
62
68
366
3666862110752,897
   > Long-term Liabilities 
850
1,171
1,854
2,266
2,205
2,912
2,9122,2052,2661,8541,171850
       Other Liabilities 
850
1,171
1,854
1,951
1,981
2,780
2,7801,9811,9511,8541,171850
> Total Stockholder Equity
16,376
8,923
1,230
42,665
26,221
16,557
16,55726,22142,6651,2308,92316,376
   Common Stock
8,187
8,208
8,208
19,975
19,975
20,050
20,05019,97519,9758,2088,2088,187
   Retained Earnings Total Equity000000
   Accumulated Other Comprehensive Income 000000
   Capital Surplus 000000
   Treasury Stock000000
   Other Stockholders Equity 
-530
-387
-405
3,683
3,749
6,168
6,1683,7493,683-405-387-530



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue10,764
Cost of Revenue-1,569
Gross Profit9,1969,195
 
Operating Income (+$)
Gross Profit9,196
Operating Expense-23,663
Operating Income-12,898-14,467
 
Operating Expense (+$)
Research Development17,452
Selling General Administrative2,354
Selling And Marketing Expenses-
Operating Expense23,66319,806
 
Net Interest Income (+$)
Interest Income21
Interest Expense-24
Other Finance Cost-0
Net Interest Income-3
 
Pretax Income (+$)
Operating Income-12,898
Net Interest Income-3
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-12,223-12,898
EBIT - interestExpense = -12,823
-12,223
-12,631
Interest Expense24
Earnings Before Interest and Taxes (EBIT)-12,799-12,199
Earnings Before Interest and Taxes (EBITDA)-12,034
 
After tax Income (+$)
Income Before Tax-12,223
Tax Provision-432
Net Income From Continuing Ops-12,655-12,655
Net Income-12,655
Net Income Applicable To Common Shares-12,655
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses7
Total Other Income/Expenses Net-3
 

Technicals of Vivoryon

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vivoryon Therapeutics NV Daily Moving Averages ChartVivoryon Therapeutics NV Daily Moving Averages Chart
1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of Vivoryon Therapeutics NV:

    Vivoryon Therapeutics NV Daily Moving Average Convergence/Divergence (MACD) ChartVivoryon Therapeutics NV Daily Moving Average Convergence/Divergence (MACD) Chart
    1.3 Directional Movement Index (DMI)

    The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

    The ADX helps you determine the strength of a trend. Let's take a look of the ADX of Vivoryon Therapeutics NV:

    • The ADX is .
    • The ADX is declining, there is no upcoming trend indication. -1
    • The +DI crossed the -DI to the downside. The trend is reversing to a down trend. -1
    Vivoryon Therapeutics NV Daily Directional Movement Index (DMI) ChartVivoryon Therapeutics NV Daily Directional Movement Index (DMI) Chart
    1.4 Parabolic SAR

    Shows the current trend and potential entry and exit signals.

    • Parabolic SAR (stop and reverse) is a lagging trend indicator.
    • Shows the current trend.
    • Shows potential entry signals.
    • Shows  potential exit signals.
    • Can be used to place trailing stoplosses..
  • The price has crossed the Parabolic SAR to the upside. The trend is reversing to an up trend. +1
  • Vivoryon Therapeutics NV Daily Parabolic SAR ChartVivoryon Therapeutics NV Daily Parabolic SAR Chart

    2. Momentum Indicators

    2.1 Relative Strength Index (RSI)

    Measures the speed and change of price movements.

    • Leading momentum indicator, meaning the signals are instant.
    • Ranges between 0 and 100.
    • Above 70 is considered overbought.
    • Below 30 is considered oversold.
    • Above or below 50 can also be used to determine price trend or support and resistance.
    • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
    • Can be used in many different ways
    • The RSI is below 50. -1
    • The RSI is below 30 and oversold. +2
    Vivoryon Therapeutics NV Daily Relative Strength Index (RSI) ChartVivoryon Therapeutics NV Daily Relative Strength Index (RSI) Chart
    2.2 Stochastic Oscillator

    Compares a certain price to multiple prices ranging over time.

    • Leading momentum indicator, meaning the signals are instant.
    • Used to determine overbought and oversold areas much like the RSI.
    • Ranges between 0 and 100.
    • Above 80 is considered overbought.
    • Below 20 is considered oversold.
    • Consists of two lines named K and D.
    • K compares the highest high and lowest low on the selected price range.
    • The D line is a moving average of the K line.
    • Can be used to spot divergences
    • The Stochastic is below 50. -1
    • The Stochastic is below 30 and oversold. +2
    Vivoryon Therapeutics NV Daily Stochastic Oscillator ChartVivoryon Therapeutics NV Daily Stochastic Oscillator Chart
    2.3 Commodity Channel Index (CCI)
    Vivoryon Therapeutics NV Daily Commodity Channel Index (CCI) ChartVivoryon Therapeutics NV Daily Commodity Channel Index (CCI) Chart
    2.4 Chande Momentum Oscillator (CMO)
    Vivoryon Therapeutics NV Daily Chande Momentum Oscillator (CMO) ChartVivoryon Therapeutics NV Daily Chande Momentum Oscillator (CMO) Chart
    2.5 Williams %R
    Vivoryon Therapeutics NV Daily Williams %R ChartVivoryon Therapeutics NV Daily Williams %R Chart

    3. Volatility Indicators

    3.1 Bollinger Bands
    Vivoryon Therapeutics NV Daily Bollinger Bands ChartVivoryon Therapeutics NV Daily Bollinger Bands Chart
    3.2 Average True Range (ATR)
    Vivoryon Therapeutics NV Daily Average True Range (ATR) ChartVivoryon Therapeutics NV Daily Average True Range (ATR) Chart

    4. Volume Indicators

    4.1 On-Balance Volume (OBV)
    Vivoryon Therapeutics NV Daily On-Balance Volume (OBV) ChartVivoryon Therapeutics NV Daily On-Balance Volume (OBV) Chart
    4.2 Money Flow Index (MFI)
    Vivoryon Therapeutics NV Daily Money Flow Index (MFI) ChartVivoryon Therapeutics NV Daily Money Flow Index (MFI) Chart

    5. Summary

    5.1. Notifications

    TypeNotificationDate
    PenkeCurrently no notifications for Vivoryon Therapeutics NV.

    5.2. Trading Signals

    DateIndicatorEntry signalExit signal
    2023-05-25DMI SHORT ENTRY LONG CLOSE

    5.2. Technical Score

    Let's check the technical score of Vivoryon Therapeutics NV based on Penke's default Symbol scanner.

    Penke's Symbol Scanner

      
      
    IndicatorConditionValue
    OpenGreater thanClose14.320
    Total1/1 (100.0%)

    Comments

    Join the conversation.

    Leave a comment

    Stay informed about Vivoryon Therapeutics NV.

    Receive notifications about Vivoryon Therapeutics NV in your mailbox!

    Penke's Market Notifications
    5XL.F
    2 hours ago

    I found you a STOCH Bearish Hidden Divergence on the daily chart of 5XL.F.

    5XL.F Daily Candlestick Chart
    5PO.SG
    3 hours ago

    I found you a STOCH Bullish Hidden Divergence on the daily chart of 5PO.SG.

    5PO.SG Daily Candlestick Chart
    5NW.F
    3 hours ago

    I found you a STOCH Bearish Reversal Divergence on the daily chart of 5NW.F.

    5NW.F Daily Candlestick Chart
    5MU.F
    3 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of 5MU.F.

    5MU.F Daily Candlestick Chart
    5HS.F
    3 hours ago

    I found you a STOCH Bullish Hidden Divergence on the daily chart of 5HS.F.

    5HS.F Daily Candlestick Chart
    5ESGG.SW
    3 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of 5ESGG.SW.

    5ESGG.SW Daily Candlestick Chart
    5ESE.MI
    3 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of 5ESE.MI.

    5ESE.MI Daily Candlestick Chart
    5C8.F
    3 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of 5C8.F.

    5C8.F Daily Candlestick Chart
    METR.BA
    4 hours ago

    I found you a STOCH Bearish Reversal Divergence on the daily chart of METR.BA.

    METR.BA Daily Candlestick Chart
    CJ5A.STU
    4 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of CJ5A.STU.

    CJ5A.STU Daily Candlestick Chart
    IRSA.BA
    4 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of IRSA.BA.

    IRSA.BA Daily Candlestick Chart
    GGAL.BA
    5 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of GGAL.BA.

    GGAL.BA Daily Candlestick Chart
    ARL.STU
    5 hours ago

    I found you a Golden Cross on the daily chart of ARL.STU.

    ARL.STU Daily Candlestick Chart
    FERR.BA
    5 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of FERR.BA.

    FERR.BA Daily Candlestick Chart
    500E.SW
    6 hours ago

    I found you a Golden Cross on the daily chart of 500E.SW.

    500E.SW Daily Candlestick Chart
    500G.LSE
    6 hours ago

    I found you a Golden Cross on the daily chart of 500G.LSE.

    500G.LSE Daily Candlestick Chart
    INX.V
    6 hours ago

    I found you a Oversold RSI (Relative Strength Index) on the daily chart of INX.V.

    INX.V Daily Candlestick Chart
    GQC.V
    6 hours ago

    I found you a RSI Bullish Reversal Divergence on the daily chart of GQC.V.

    GQC.V Daily Candlestick Chart
    MMS.V
    7 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of MMS.V.

    MMS.V Daily Candlestick Chart
    VRR.V
    7 hours ago

    I found you a STOCH Bearish Reversal Divergence on the daily chart of VRR.V.

    VRR.V Daily Candlestick Chart
    4XJ.F
    7 hours ago

    I found you a STOCH Bearish Reversal Divergence on the daily chart of 4XJ.F.

    4XJ.F Daily Candlestick Chart
    4UB9.XETRA
    7 hours ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of 4UB9.XETRA.

    4UB9.XETRA Daily Candlestick Chart
    4RO.F
    7 hours ago

    I found you a Golden Cross on the daily chart of 4RO.F.

    4RO.F Daily Candlestick Chart
    ATHX.NASDAQ
    7 hours ago

    I found you a STOCH Bearish Reversal Divergence on the daily chart of ATHX.NASDAQ.

    ATHX.NASDAQ Daily Candlestick Chart